FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期： 2025年6月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 – 1 – 股權架構 本公司緊接及緊隨轉換及上市完成前後的股權架構載列如下： （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 內幕消息 完成2024年H股全流通 本公告乃由北京鷹瞳科技發展股份有限公司（「本公司」）根據香港法例第571章證券 及期貨條例第XIVA部及香港聯合交易所有限公司（「聯交所」）證券上市規則第 13.09(2)(a)條而作出。 茲提述日期為2025年4月28日及2025年5月26日的公告（「該等公告」），內容有關本公 司接獲中國證監會就其2024年H股全流通及聯交所就轉換H股上市及買賣授出的批 准。除文義另有所指外，本公告所用詞彙與該等公告所界定者具有相同涵義。 完成轉換及上市 本公司欣然宣佈，50,151,012股未上市股份轉換為H股已於2025年6月13日完成 ...

Investment Rating - The report maintains a positive outlook on the Hong Kong stock market, indicating a strong risk appetite and suggesting investment opportunities in various sectors, particularly in virtual assets and Web 3.0 [3][10]. Core Insights - The Hong Kong stock market is experiencing a significant increase in risk appetite, with improved asset quality and trading volume, highlighting the value of asset trading platforms [3][10]. - There is a notable uptrend in multiple sectors such as AI, new consumption, and innovative pharmaceuticals, with a particular focus on small and mid-cap stocks in media and consumer sectors [3][10]. - The report emphasizes the ongoing development of virtual assets and the Web 3.0 market, driven by stablecoin policies and recent IPOs, suggesting that more regulatory frameworks will emerge [3][10]. - The trend of Chinese companies returning to Hong Kong for IPOs is gaining momentum, with increased trading of companies like NetEase and Ctrip in the Hong Kong market [3][10]. - The valuation of overseas Chinese assets remains influenced by US-China trade relations and the broader economic environment, necessitating close monitoring of trade policies and domestic economic changes [3][10]. Summary by Sections Education - The K12 education sector maintains high growth, with leading institutions reporting over 20% revenue growth during the winter training period, and an increase in non-academic course retention rates [5][11]. Luxury Goods - The luxury goods market shows slight pressure due to macroeconomic factors, but brands that align with demand trends are performing well, with cautious price increases observed [5][20]. Coffee and Tea Drinks & OTA - Coffee and tea remain key categories for delivery platforms, with strong performance from major brands like Luckin Coffee, which continues to expand its store presence [5][25]. E-commerce - The e-commerce sector faces slight pressure, but major platforms like Alibaba and JD.com are expected to benefit from ongoing promotional activities [5][26]. Streaming Platforms - Music streaming platforms are viewed as high-quality internet assets, with sustained profitability driven by scale effects [5][34]. Virtual Assets & Internet Brokers - The stablecoin leader Circle's IPO saw a 168% increase on its first day, marking a significant event in the virtual asset space [5][38]. Real Estate Transactions - Recent data shows a slight decline in second-hand housing transactions in major cities, suggesting a need for caution in the real estate market [5][50]. Automotive Services - The automotive aftermarket is under pressure, with traditional fuel vehicle service visits declining, while new energy vehicle service visits are increasing [5][45].

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 2024年股東週年大會通告 茲通告北京鷹瞳科技發展股份有限公司（「本公司」）謹訂於2025年6月27日（星期五） 上午十一時正假座中國北京市海淀區西三環北路甲2號院2號樓4層21室舉行2024年 股東週年大會（「股東週年大會」）以供股東審議並酌情批准以下本公司決議案。除文 義另有所指外，本通告所用詞彙與本公司日期為2025年5月28日的通函（「通函」）所 界定者具有相同涵義。 普通決議案 – 1 – (1) 審議及批准本公司2024年度董事會報告。 (2) 審議及批准本公司2024年度監事會報告。 (3) 審議及批准本公司及其附屬公司2024年度年報。 (4) 審議及批准本公司及其附屬公司2024年度財務決算報告。 (5) 審議及批准本 ...

此 乃 要 件 請 即 處 理 閣下如對本通函有疑問，應諮詢 閣下的股票經紀、其他註冊證券交易商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已出售或轉讓名下所有北京鷹瞳科技發展股份有限公司股份，應立即將本通函連同代表委任 表格送交買方或承讓人或經手買賣或轉讓的銀行、股票經紀或其他代理商以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） (1)2024年董事會報告 (2)2024年監事會報告 (3)2024年年度報告 (4)2024年財務決算報告 (5)2025年財務預算 (6)2024年利潤分配方案 (7)續聘核數師 (8)建議委任一名董事 (9)動用閒置資金進行現金管理 (10)發行新股的一般授權 (11)購回H股的一般授權 及 2024年股東週年大會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 聯交所授出2024年H股全流通之上市批准 緒言 茲提述北京鷹瞳科技發展股份有限公司（「本公司」）日期為2024年8月28日及2025年4 月28日的公告，以及本公司日期為2024年9月27日的通函，內容有關（其中包括）本 公司申請2024年H股全流通並接獲中國證監會審批。除另有說明外，本公告所用詞 彙與上述公告及通函所界定者具有相同涵義。 上市批准 本公司欣然宣佈，其近日接獲聯交所就50,151,012股H股（「轉換H股」）（相當於根據 2024年H股全流通項下轉換及上市將轉換為H股的未上市股份最高數目）上市及買 賣的批准（須待達成轉換及上市的所有其他條件後方可作實）。 – 1 – 股權架構 轉換及上市將涉及共計26名參與持有人（「參與 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告由北京鷹瞳科技發展股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.51(2)及13.51(1)條作出。 監事辭任 本公司董事（「董事」）會（「董事會」）謹此宣佈，魏宇博先生（「魏先生」）因本集團內部 調動，已呈辭本公司監事（「監事」）一職，自本公告日期起生效。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 監事辭任 及 建議委任董事及監事 董事會亦欣然宣佈，羅玉潔女士（「羅女士」）於本公司職工代表大會上獲選為職工代 表監事。於2025年5月26日舉行的監事會會議上，羅女士進一步當選為監事會主 席。 魏先生及羅女士的履歷詳情如下： 魏先生已確認，彼與本公司、董事會及本公司監事會（「監事會」） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 – 1 – 量之詳情請參閱該公告及通函。於本公告日期，本次H股全流通以及轉換及上市的 詳細實施計劃尚未最終確定。本公司將根據內幕消息條文及╱或上市規則的要求就 本次H股全流通以及轉換及上市的進展情況作出進一步公告。 本次H股全流通以及轉換及上市尚須履行中國證監會、聯交所及其他境內外監管機 構所要求的其他相關程序。本公司股東及有意投資者於買賣本公司證券時務請審慎 行事。 承董事會命 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 內幕消息 中國證監會批准H股全流通 本公告乃由北京鷹瞳科技發展股份有限公司（「本公司」）根據香港法例第571章證券 及期貨條例第XIVA部（「內幕消息條文」）及香港聯合交易所有限公司（「聯交所」）證 券上市規則（「上市規則」）第1 ...

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 156,367,000, a decrease of 23.3% compared to RMB 203,964,000 in 2023[14] - Gross profit for 2024 was RMB 86,676,000, down from RMB 125,133,000 in 2023, reflecting a gross margin decline[14] - Loss before tax increased to RMB 268,701,000 in 2024, compared to RMB 145,859,000 in 2023, indicating a worsening financial position[14] - The company reported a loss per share of RMB 2.50 for 2024, compared to RMB 1.28 in 2023, indicating increased losses on a per-share basis[14] - Net assets decreased to RMB 1,276,602,000 in 2024 from RMB 1,557,784,000 in 2023, a reduction of 18.0%[14] - Revenue decreased by 23.3% from RMB204.0 million for the year ended December 31, 2023 to RMB156.4 million for the year ended December 31, 2024, primarily due to the impact of myopia prevention and control product policies[160] - Cost of sales decreased by 11.6% from RMB78.8 million for the year ended December 31, 2023 to RMB69.7 million for the year ended December 31, 2024, attributed to reduced revenue and improved efficiency[163] - Gross profit decreased from RMB125.1 million for the year ended December 31, 2023 to RMB86.7 million for the year ended December 31, 2024, with gross profit margin declining from 61.4% to 55.4%[164] - Other income and gains decreased from RMB58.1 million for the year ended December 31, 2023 to RMB32.2 million for the year ended December 31, 2024, mainly due to reduced interest income[168] - R&D expenses decreased by 8.9% from RMB111.6 million for the year ended December 31, 2023 to RMB101.7 million for the year ended December 31, 2024, due to strengthened project management and reduced labor costs[169] - Selling and distribution expenses decreased by 25.3% from RMB100.6 million for the year ended December 31, 2023 to RMB75.2 million for the year ended December 31, 2024, primarily due to centralized management and personnel optimization[175] - Administrative expenses increased by 12.7% from RMB99.0 million for the year ended December 31, 2023 to RMB111.6 million for the year ended December 31, 2024, primarily due to increased employee termination payments[176] - The company recorded a loss of RMB265.1 million for the year ended December 31, 2024, compared to a loss of RMB145.7 million for the year ended December 31, 2023, representing an increase in loss of 82.1%[184] - The increase in loss was primarily due to a loss allowance of RMB23.7 million related to regulatory changes affecting laser-based myopia treatment devices, an increase of RMB22.3 million in share-based payments, and an impairment of goodwill of RMB43.2 million[184] Asset Management - Total current assets decreased to RMB 894,222,000 in 2024 from RMB 1,281,927,000 in 2023, a decline of 30.2%[14] - Non-current assets increased significantly to RMB 517,244,000 in 2024, up from RMB 402,985,000 in 2023, showing investment in long-term assets[14] - Current liabilities increased to RMB 122,391,000 in 2024 from RMB 110,237,000 in 2023, reflecting a rise in short-term financial obligations[14] - The company's property, plant, and equipment decreased to RMB16.5 million as of December 31, 2024, from RMB18.0 million as of December 31, 2023, primarily due to depreciation and cleanup of damaged equipment[186] - Inventories decreased to RMB31.2 million as of December 31, 2024, from RMB40.1 million as of December 31, 2023, due to sales-oriented production and improved inventory management[191] - Trade receivables decreased to RMB46.5 million as of December 31, 2024, from RMB79.6 million as of December 31, 2023, attributed to a decrease in gross trade receivables and an increase in impairment loss[192] - The company recognized a loss allowance of RMB39.2 million for trade receivables during the reporting period, with RMB23.7 million related to sales contracts of laser-based myopia treatment devices[193] Product Development and Innovation - The company plans to strengthen its technological foundation and optimize operational efficiency to address market challenges[16] - In 2024, the company maintained the competitiveness of its existing algorithm platforms while making significant progress in the research and development of Large Language Models and successfully filed a national deep synthesis service algorithm[17] - The company launched two landmark portable fundus cameras, the AI-FUNDUSCAMERA-M series and the new generation P-series, enhancing clinical applications and expanding its product matrix[20] - The non-invasive light-based myopia treatment device utilizing PBM-LED technology received medical device certification from the NMPA, becoming the first product of its kind in China to achieve this certification[22] - The company is strategically expanding from a B-end service solution provider to also offering C-end health solutions with the new P-series portable fundus camera scheduled for launch in 2025[21] - The integrated intelligent medical product matrix includes systems for fundus disease detection, myopia prevention, and visual function training, consolidating the company's leading position in intelligent medical treatment[19] - The company has developed a comprehensive product matrix that includes three major AI-enabled medical product lines: Retinal Detection AI, Myopia Prevention and Control AI, and Visual Training AI[51] - The dual-engine strategy of precise detection and innovative treatment enhances market operation synergy and expands product reach to various healthcare settings[44] - Airdoc's AI-empowered retinal image recognition technology addresses significant unmet medical needs for early detection and diagnosis of chronic diseases[52] - The visual training AI product series incorporates AI-powered eye-tracking and training modules, achieving innovative breakthroughs in clinical applications[53] - The company has adjusted its product pipeline to focus on integrated diagnosis and treatment products in response to market demand[63] - The myopia treatment device has been integrated with a self-developed large language model, enhancing its capabilities as a "home optometrist" for personalized intervention[140] - The company continues to invest in R&D for the WanYu LLM technology, integrating it into products and services for enhanced medical solutions[155] Market Expansion and Strategy - Airdoc aims to expand application scenarios to solidify the groundwork for long-term development amidst industry policy adjustments[16] - The company plans to optimize its organization and improve efficiency in 2025, aiming to significantly narrow losses and increase the revenue share of treatment services[31] - National policies have stabilized, with LED-based myopia control products officially categorized as Class II medical devices, which is expected to boost revenues for the company's products[30] - The company aims to enhance its global footprint by expanding into markets such as Malaysia, Singapore, Thailand, the UAE, and South Africa, with a focus on the Middle East in 2025[152] - The company plans to expand sales channels for AI-assisted diagnostics and invest in treatment businesses, including myopia prevention and visual training, to consolidate long-term strategy[151] Regulatory and Compliance - Regulatory changes from the NMPA impacted the company's laser-based AI myopia prevention products, leading to a decrease in revenue and an impairment of goodwill related to the acquisition of Beijing Zhitong Technology Co., Ltd.[28] - The NMPA issued a notice in June 2023 that stipulates laser myopia treatment devices without Class III medical device certification will not be permitted for production and sales in the PRC effective July 1, 2024[199] Customer Engagement and Service Growth - The company achieved significant growth in the number of primary healthcare sites in 2024, broadening service coverage and enhancing customer access to professional services[27] - The number of active service sites increased from 5,671 to 7,883, representing a year-over-year growth of 39.01%[45] - During the reporting period, Airdoc detected 7.10 million cases, reflecting a year-over-year increase of 3.87%[45] - In 2024, there was a more than 50% year-over-year increase in the number of unique visitors (UVs) in hospitals and primary healthcare within the Airdoc Medical segment[46] - The number of active hospital service sites covered reached 417, representing a year-over-year increase of 51.1%, with detections conducted reaching 401 thousand, up by 65.5% year-over-year[120] - The number of active primary healthcare institution service sites reached 2,092, representing a year-over-year increase of 71.3%, with detections conducted reaching 1,034 thousand, up by 62.6% year-over-year[120] - The company has implemented AI-based solutions in over 350 health checkup centers across China, with some achieving a repurchase rate of over 50% for SaMD products[120] Research and Development Achievements - The company has published over 20 papers in prestigious peer-reviewed journals, validating its AI-empowered early detection and diagnostic solutions[83] - The company has published over 20 papers in influential AI academic conferences, enhancing its credibility in the field[85] - Airdoc-AIFUNDUS has been trained on data from 15 different organizations in China, covering a significant portion of the national population, ensuring effective product applicability across diverse demographics[88] - Airdoc's AI technology has been validated through clinical trials, supporting its early detection and diagnostic solutions for chronic diseases[85] - Research collaboration with Fudan University resulted in a publication demonstrating a novel postoperative refractive power prediction method with greater accuracy than existing methods[92] Patent and Intellectual Property - During the reporting period, Airdoc was granted 40 new patents, bringing the total to 270 patents, including 128 inventions[100] - The company has developed SaMD products for glaucoma and cataracts detection, which received Class II medical device certification in June 2020 and January 2022 respectively[67] - The health risk assessment solution currently supports the identification of 55 types of lesions and disease risks, catering to diverse healthcare needs[70]

Group 1 - The core idea of the news is the integration of AI technology in grassroots healthcare services in Wuyishan City, enhancing chronic disease prevention and management for the elderly and high-risk populations [1][3][5] - Wuyishan City has launched a free health check-up program for individuals aged 65 and above, incorporating new tests for glycosylated hemoglobin and AI retinal screening, creating a closed-loop system for chronic disease management [3][5] - As of early April, 2,228 diabetes patients have undergone screenings for diabetic retinopathy and glaucoma, with 296 high-risk cases identified, allowing timely medical intervention [3] Group 2 - The local health bureau has implemented a three-year action plan for integrated chronic disease management, focusing on expanding and enhancing services for diabetes patients through AI retinal examinations [5][7] - The Airdoc-AIFUNDUS 2.0 software has received certification from the National Medical Products Administration (NMPA), enhancing diagnostic capabilities for various eye diseases in primary healthcare settings [7] - The integration of AI technology is expected to make grassroots healthcare services more intelligent and precise, contributing to the "Healthy China" initiative and improving access to quality medical resources [7]